Phase I Clinical Trial on Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Dendritic cells; Stem cell therapies
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms myDCTV
- 25 Nov 2021 New trial record
- 28 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2020 Planned End Date changed from 1 Oct 2019 to 1 Oct 2023.